MYGN Myriad Genetics Inc.

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Management will participate in two upcoming investor healthcare conferences

SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first quarter 2025.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at . To participate in the live conference call via telephone, please register . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at following the call.

Upcoming Q2 Investor Conferences

Management plans to participate in the following investor healthcare conferences:

  • The BofA Securities 2025 Health Care Conference – fireside chat at 3:00 pm EDT on Wednesday, May 14, 2025.
  • Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm EDT on Wednesday, June 11, 2025.

Live and archived webcasts of all presentations can be viewed at .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit .

Investor Contact 

Matt Scalo 

(801) 584-3532 

 

Media Contact 

Kate Schraml

(224) 875-4493

  



EN
29/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE

Concerns about Mental Health Medication Side Effects Remain a Barrier ...

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor More than half say genetic testing for mental health medications could reduce concerns SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medicatio...

 PRESS RELEASE

Myriad Genetics to Release First Quarter 2025 Financial Results on May...

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 Management will participate in two upcoming investor healthcare conferences SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance ...

 PRESS RELEASE

Myriad Genetics Highlights MRD Clinical Validity Data at American Asso...

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting Podium presentation showcases the clinical application of Precise™ MRD SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) Annual Meeting that highlights the performance of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). A podium presentation titled ...

 PRESS RELEASE

Myriad Genetics Announces Study Results Show Patients with Depression ...

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing Study published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a showing those with major depressive disorder had fewer psychiatric hospitalizations after taking the ® Psychotropic Test. “Millions of Americans face major depressive disorder each ...

 PRESS RELEASE

Myriad Genetics Announces Inducement Awards

Myriad Genetics Announces Inducement Awards SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performance-based restricted stock units (PSUs) equal to $1.75 mill...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch